Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma

Leuk Lymphoma. 2022 Dec;63(13):3217-3221. doi: 10.1080/10428194.2022.2118537. Epub 2022 Sep 7.

Authors

Leisa R Watson¹, Thomas E Lew^{1

2}, Lucy C Fox^{1

3

4}, Amit Khot^{1

4}, Carrie van der Weyden¹

Affiliations

¹ Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
² Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
³ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

PMID: 36070587
DOI: 10.1080/10428194.2022.2118537

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, T-Cell* / diagnosis
Lymphoma, T-Cell* / pathology
Lymphoma, T-Cell* / therapy
Lymphoma, T-Cell, Cutaneous*
Panniculitis* / diagnosis
Panniculitis* / etiology
Panniculitis* / therapy
Skin Neoplasms* / pathology

Substances

ruxolitinib

Supplementary concepts

Subcutaneous panniculitis-like T-cell lymphoma